NFXF Blog

Harmony Biosciences recently announced results from its Phase 3 RECONNECT study of ZYN002, a cannabidiol (CBD) gel being tested for Fragile X syndrome.

Bowen’s FX Therapeutics, a company with roots in the Fragile X community, is advancing efforts toward a future protein replacement therapy.

The NFXF joined researchers and clinicians at the 6th International Conference on Fragile X Premutation Associated Conditions in Italy to advance understanding of FXTAS, FXPOI, and related conditions, update treatment recommendations, and strengthen global Fragile X collaboration.

Congratulations to 2025’s three NFXF Summer Scholars. Meet Susana Lopez-Ignacio, Tanvi Kamra, and Shelby Dauterman!

On Tuesday, July 22, the Rhode Island State House held a special lighting called Lighting the Way for Fragile X in honor of National Fragile X Awareness Day. And, of course, all of the Little Rhody Warriors were there!

We’re thrilled to spotlight a major new review article recently published in the New England Journal of Medicine (NEJM) – The Spectrum of Fragile X Disorders by Randi J. Hagerman and Paul J. Hagerman.

The Belonging Project aims to intentionally extend our reach to underserved and underrepresented communities across the United States. We have 2025 updates from three Fragile X clinics and our belongingness survey, and we will keep you updated as we continue to move forward.

Moshi Moshi is hosting their 6th annual fundraiser to support the NFXF during Fragile X Awareness Month in July.

Nancy Carlson and the NFXF Heartland Chapter — Iowa and South Dakota hosted their 10th Annual Bike To X Out Fragile X on Saturday, June 7, 2025, in Des Moines, Iowa.